- Home
- CTRM vs CMMB Comparison
CTRM vs CMMB Comparison
Compare CTRM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- CMMB
- Stock Information
- Founded
- CTRM 2016
- CMMB 2004
- Country
- CTRM Cyprus
- CMMB Israel
- Employees
- CTRM N/A
- CMMB N/A
- Industry
- CTRM Marine Transportation
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- CMMB Health Care
- Exchange
- CTRM Nasdaq
- CMMB Nasdaq
- Market Cap
- CTRM 21.2M
- CMMB 22.0M
- IPO Year
- CTRM N/A
- CMMB N/A
- Fundamental
- Price
- CTRM $1.97
- CMMB $3.09
- Analyst Decision
- CTRM
- CMMB Strong Buy
- Analyst Count
- CTRM 0
- CMMB 2
- Target Price
- CTRM N/A
- CMMB $26.50
- AVG Volume (30 Days)
- CTRM 31.4K
- CMMB 136.3K
- Earning Date
- CTRM 11-06-2025
- CMMB 08-14-2025
- Dividend Yield
- CTRM N/A
- CMMB N/A
- EPS Growth
- CTRM N/A
- CMMB N/A
- EPS
- CTRM N/A
- CMMB N/A
- Revenue
- CTRM $66,197,291.00
- CMMB N/A
- Revenue This Year
- CTRM N/A
- CMMB N/A
- Revenue Next Year
- CTRM N/A
- CMMB N/A
- P/E Ratio
- CTRM N/A
- CMMB N/A
- Revenue Growth
- CTRM N/A
- CMMB N/A
- 52 Week Low
- CTRM $1.95
- CMMB $2.99
- 52 Week High
- CTRM $4.64
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- CTRM 30.76
- CMMB 24.58
- Support Level
- CTRM $2.02
- CMMB $2.99
- Resistance Level
- CTRM $2.10
- CMMB $3.86
- Average True Range (ATR)
- CTRM 0.07
- CMMB 0.26
- MACD
- CTRM -0.01
- CMMB -0.02
- Stochastic Oscillator
- CTRM 6.67
- CMMB 8.85
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.